Sun Pharmaceutical Industries has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for generic version of Depo-Testosterone Injection, Testosterone Cypionate Injection USP, 100 mg/ml and 200mg/ml.
This generic Testosterone Cypionate Injection USP, 100 mg/mL and 200mg/mL is therapeutically equivalent to Depo-Testosterone Injection of Pfizer Inc and is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. As per April-2013, IMS MAT, the product had annual revenues of approximately $130 million in the US.
Sun Pharmaceuticals Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
